Coenzyme Q in serum and muscle of 5 patients with Kearns-Sayre syndrome and 12 patients with ophthalmoplegia plus.
Coenzyme Q10 (CoQ) was measured in serum and muscle of 17 patients with ophthalmoplegia plus (including 5 patients with Kearns-Sayre syndrome), in muscle of 9 patients with neurogenic atrophies, 5 patients with myositis, and 5 patients with progressive muscular dystrophies (including 1 patient with oculopharyngeal dystrophy), and in serum and muscle of normal controls. CoQ was markedly decreased in serum and muscle of 1 patient with Kearns-Sayre syndrome and treatment with CoQ resulted in a significant clinical improvement. The other 4 patients with Kearns-Sayre syndrome and the patients with ophthalmoplegia plus exhibited normal concentrations of CoQ in serum and muscle. CoQ levels in muscle of patients with progressive muscular dystrophies, myositis or neurogenic atrophies were within the normal range. Concentrations of CoQ in serum and muscle of normal controls were independent of age and showed no sex difference. The data indicate that CoQ deficiency might be the specific cause of mitochondrial encephalomyopathy in 1 patient but it was not the underlying defect common to all cases with Kearns-Sayre syndrome and ophthalmoplegia plus, although the possibility of a focal CoQ deficiency affecting only single muscle fibres cannot be excluded.
Zierz
S
S
Neurologische Universitätsklinik, Bonn, Federal Republic of Germany.
Jahns
G
G
Jerusalem
F
F
D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D007625:Kearns-Sayre Syndrome / Q000201:enzymology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000201:enzymology* / Q000503:physiopathology; D009886:Ophthalmoplegia / Q000201:enzymology* / Q000503:physiopathology; D014451:Ubiquinone / Q000378:metabolism*
D014451:Ubiquinone